Clinical Trials Directory

Trials / Completed

CompletedNCT03544749

A Comparison of Ambu® AuraGain™ Laryngeal Mask Airway and I-gel in Adult

A Randomized Comparison of Ambu® AuraGain™ Laryngeal Mask Airway and I-gel in Patients With Simulated Cervical Immobilization

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
104 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The supraglottic airway device(SAD), as an alternative to the endotracheal tube is inserted into the oral cavity and seals the upper esophagus and the surrounding tissue, effectively securing airway. SAD has evolved in recent years to increase efficiency and secure safety. The recently developed Ambu® AuraGain™ is a second-generation SAD with a built-in gastric port and is designed to be fitted well in the larynx and oral cavity after insertion because the shaft is bent at an angle of 90 degrees and has an inflatable cuff. In a previous study, Ambu® AuraGain™ showed a higher sealing pressure and better fibreoptic finding compared to LMA Supreme in laparoscopic surgery. On the other hand, I-gel and Ambu® AuraGain™, both of the second-generation SAD, show comparatively excellent performance according to the results of previous studies. However, there are no studies comparing the characteristics of two airway devices in adults. The purpose of this study is to compare the performance of I-gel and Ambu® AuraGain™ to make a difficult airway-like situation using cervical collar for adult patients receiving mechanical ventilation under general anesthesia.

Conditions

Interventions

TypeNameDescription
DEVICEAmbu® AuraGain™After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
DEVICEI-gelAfter induction of anesthesia, I-gel will be inserted for the mechanical ventilation.

Timeline

Start date
2018-06-07
Primary completion
2018-09-27
Completion
2018-10-12
First posted
2018-06-04
Last updated
2019-07-18

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03544749. Inclusion in this directory is not an endorsement.